Nordicus Partners Corp. Files 8-K with Historical Name Changes

Ticker: NORD · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1011060

Sentiment: neutral

Topics: corporate-history, filing-update

TL;DR

Nordicus Partners (formerly EKIMAS, AdvanSource, CARDIOTECH) filed an 8-K on 8/11/25.

AI Summary

Nordicus Partners Corp. filed an 8-K on August 11, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing indicates the company was formerly known as EKIMAS Corp, AdvanSource Biomaterials Corp, and CARDIOTECH INTERNATIONAL INC, with name changes occurring on April 6, 2020, October 21, 2008, and March 21, 1996, respectively. The company is incorporated in Delaware and its fiscal year ends on March 31.

Why It Matters

This filing provides historical context for Nordicus Partners Corp. by detailing its previous corporate identities, which can be important for understanding its long-term trajectory and potential legacy issues.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting historical information and does not appear to contain any new material events or financial disclosures that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily for a Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was Nordicus Partners Corp. incorporated?

Nordicus Partners Corp. is incorporated in Delaware.

What are the previous names of Nordicus Partners Corp.?

Nordicus Partners Corp. was formerly known as EKIMAS Corp, AdvanSource Biomaterials Corp, and CARDIOTECH INTERNATIONAL INC.

On what date did the company last change its name from CARDIOTECH INTERNATIONAL INC?

The name change from CARDIOTECH INTERNATIONAL INC occurred on March 21, 1996.

What is the fiscal year end for Nordicus Partners Corp.?

The fiscal year end for Nordicus Partners Corp. is March 31.

Filing Stats: 904 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2025-08-11 14:45:23

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure In accordance with Regulation FD, we are furnishing certain valuation reports (the "Valuations") that Nordicus Partners Corporation (the "Company") may furnish to analysts, investors and others regarding its wholly owned subsidiaries, Orocidin A/S ("Orocidin") and Bio-Convert A/S ("Bio-Convert"), on or after August 11, 2025. The Valuations are attached hereto as Exhibits 99.1 through 99.2 and will be available on the Company's website at nordicuspartners.com . The Valuations were prepared solely for the purpose of assisting the Board of Directors in evaluating Orocidin's and Bio-Convert's fair market value and should not be relied upon for any other purpose. The independent Valuations were performed by Stanton Park Advisors LLC, which not is affiliated with the Company. The specific valuation methods used by Stanton Park Advisors in the determination of value were based upon the performance of investigative procedures that Stanton Park Advisors considered necessary under the circumstances. These procedures include discussions with Orocidin's and Bio-Convert's management regarding the history of the business, as well as detailed discussions of Orocidin's and Bio-Convert's recent financial performance and operations; its expected future performance; and other factors Stanton Park Advisors considered relevant. Stanton Park Advisors evaluated internal and external factors influencing the value of Orocidin and Bio-Convert, respectively, which were reviewed, analyzed, and interpreted. Internal factors included Orocidin's and Bio-Convert's respective financial positions, results of their respective operations, and the size and marketability of the interest being valued. External factors included – among other things – the status of the industry and the position of Orocidin and Bio-Convert relative to the industry. This report contains forward-looking statements, including financial projections used in the Valuation analyses. Actual

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 99.1 Stanton Park Advisors LLC , Valuation of Bio-Convert's QR-02 as of June 30, 2025 99.2 Stanton Park Advisors LLC , Valuation of Orocidin's QR-01 as of June 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: August 11, 2025 Nordicus Partners Corporation By: /s/ Henrik Rouf Henrik Rouf Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing